From: The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Studya | Patients | Drugs | Number | FPG | HbA1c | Weight loss | SBP |
---|---|---|---|---|---|---|---|
CANTATA-SU [99] | T2DM patients with 7.0–9.5% HbA1c | Canagliflozin 100 mg | 483 | − 1.35 | − 0.82 | − 3.7 | − 3.3 |
Canagliflozin 300 mg | 485 | − 1.52 | − 0.93 | − 4.0 | − 4.6 | ||
Glimepiride | 482 | − 1.02 | − 0.81 | 0.7 | 0.2 | ||
Lavalle-González et al. [100] | Patients with T2DM had inadequate glycaemic control | Sitagliptin | 366 | − 1.0 | − 0.73 | − 1.3 | − 0.7 |
Canagliflozin 100 mg | 368 | − 1.5 | − 0.73 | − 3.8 | − 3.5 | ||
Canagliflozin 300 mg | 367 | − 2.0 | − 0.88 | − 4.2 | − 4.7 | ||
Placebo/sitagliptin | 183 |  | − 0.17c | − 1.2c |  | ||
Bruce Bode [101] | Patients with 7.0% ≤ HbA1c ≤ 10.0% | Placebo | 237 | 0.4 | − 0.03 | − 0.1 | 1.1 |
Canagliflozin 100 mg | 241 | − 1.0 | − 0.60 | − 2.2 | − 3.5 | ||
Canagliflozin 300 mg | 236 | − 1.1 | − 0.73 | − 2.8 | − 6.8 | ||
Michael Roden et al. [108] | Adults had no treatment in the previous 12 weeks | Placebo | 228 | 0.65 | 0.08 | − 0.33 | − 0.3 |
Empagliflozin 10 mg | 224 | − 1.08 | − 0.66 | − 2.26 | − 2.9 | ||
Empagliflozin 25 mg | 224 | − 1.36 | − 0.78 | − 2.48 | − 3.7 | ||
Sitagliptin | 223 | − 0.38 | − 0.66 | 0.18 | 0.5 | ||
Ferrannini [110] | Patients with T2DM | Empagliflozin 10 mg | 80 | − 30b | − 0.34 | − 2.2 | 0.1 |
Empagliflozin 25 mg | 88 | − 28b | − 0.47 | − 2.6 | − 1.7 | ||
Metformin | 56 | − 26b | − 0.56 | − 1.3 | 2.0 | ||
Duration-8 [121] | Patients with T2DM inadequately controlled by metformin | Exenatide plus dapagliflozin | 228 | − 3.66 | − 2.0 | − 3.55 | − 4.3 |
Exenatide | 227 | − 2.54 | − 1.6 | − 1.56 | − 1.2 | ||
Dapagliflozin | 230 | − 2.73 | − 1.4 | − 2.22 | − 1.8 | ||
Weber et al. [89] | Patients with inadequately controlled T2DM and hypertension | Placebo | 224 | 0.2 | − 0.02 | − 0.59 | − 7.62 |
Dapagliflozin | 225 | − 1.0 | − 0.63 | − 1.44 | − 11.90 | ||
VERTIS Asia [123] | Patients with T2DM inadequately controlled on metformin | Placebo | 167 | − 6.7b | − 0.2 | − 1.2 | 0.2 |
Ertugliflozin 5 mg | 170 | − 37.1b | − 1.0 | − 3.0 | − 5.1 | ||
Ertugliflozin 15 mg | 169 | − 34.5b | − 0.9 | − 3.2 | − 3.9 | ||
VERTIS MET [126] | Adults with T2DM inadequately controlled on metformin | Placebo/glimepiride | 209 | − 0.6 | − 0.6 | − 0.18 | 0.05 |
Ertugliflozin 5 mg | 207 | − 1.0 | − 0.6 | − 3.77 | − 3.61 | ||
Ertugliflozin 15 mg | 205 | − 1.6 | − 0.9 | − 3.63 | − 3.13 | ||
VERTIS FACTORIAL [127] | Patients with HbA1c ≥ 7.5% and ≤ 11.0% | Ertugliflozin 5 mg | 250 | − 28.7 | − 1.0 | − 2.4 | − 2.7 |
Ertugliflozin 15 mg | 248 | − 30.8 | − 0.9 | − 3.2 | − 1.6 | ||
Sitagliptin | 247 | − 15.2 | − 0.8 | − 0.1 | − 0.2 | ||
Ertugliflozin 5 mg/sitagliptin | 243 | − 39.3 | − 1.4 | − 2.4 | − 2.3 | ||
Ertugliflozin 15 mg/sitagliptin | 244 | − 41.8 | − 1.4 | − 2.8 | − 2.2 |